Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes

Jeffrey Kline, Jackeline Hernandez, Melanie M. Hogg, Alan E. Jones, D. Mark Courtney, Christopher Kabrhel, Kristen E. Nordenholz, Deborah B. Diercks, Matthew T. Rondina, James R. Klinger

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Submassive pulmonary embolism (PE) has a low mortality rate but can degrade functional capacity. Objective: The present study aims to provide rationale, methodology, and initial findings of a multicentre, randomised trial of fibrinolysis for PE that used a composite end-point, including quality of life measures. Methods: This investigator-initiated study was funded by a contract between a corporate partner and the investigator's hospital (the prime site). The investigator was the Food and Drug Administration (FDA) sponsor. The prime site subcontracted, indemnified, and trained consortia members. Consenting, normotensive patients with PE and right ventricular strain (by echocardiography or biomarkers) received low-molecular-weight heparin and random assignment to a single bolus of tenecteplase or placebo in double-blinded fashion. The outcomes were: (i) in-hospital rate of intubation, vasopressor support, and major haemorrhage, or (ii) at 90 days, death, recurrent PE, or composite that defined poor quality of life (echocardiography, 6min walk test and surveys). The planned sample size was n = 200. Results: Eight sites enrolled 87 patients over 5 years. The ratio of patients screened for each enrolled was 7.4 to 1, equating to 11h screening time per patient enrolled. Primary barrier to enrolment was the cost of screening. Two patients died (2.5%, 95%CI [0-8%]), one developed shock, but 18 (22%, 95%CI: [13-30%]) had a poor quality of life. Conclusions: An investigator-initiated, FDA-regulated, multicentre trial of fibrinolysis for submassive PE was conducted, but was limited by screening costs and a low mortality rate. Quality of life measurements might represent a more important patient-centred end-point.

Original languageEnglish (US)
Pages (from-to)515-526
Number of pages12
JournalEMA - Emergency Medicine Australasia
Volume25
Issue number6
DOIs
StatePublished - Dec 1 2013

Fingerprint

Fibrinolysis
Pulmonary Embolism
Multicenter Studies
Quality of Life
Research Personnel
United States Food and Drug Administration
Echocardiography
Costs and Cost Analysis
Mortality
Low Molecular Weight Heparin
Contracts
Intubation
Sample Size
Shock
Biomarkers
Placebos
Hemorrhage

Keywords

  • Controlled trial
  • Fibrinolysis
  • Indemnification
  • Methodology
  • Thrombolysis
  • Venous thromboembolism

ASJC Scopus subject areas

  • Emergency Medicine

Cite this

Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. / Kline, Jeffrey A.; Hernandez, Jackeline; Hogg, Melanie M.; Jones, Alan E.; Courtney, D. Mark; Kabrhel, Christopher; Nordenholz, Kristen E.; Diercks, Deborah B.; Rondina, Matthew T.; Klinger, James R.

In: EMA - Emergency Medicine Australasia, Vol. 25, No. 6, 01.12.2013, p. 515-526.

Research output: Contribution to journalArticle

Kline, JA, Hernandez, J, Hogg, MM, Jones, AE, Courtney, DM, Kabrhel, C, Nordenholz, KE, Diercks, DB, Rondina, MT & Klinger, JR 2013, 'Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes', EMA - Emergency Medicine Australasia, vol. 25, no. 6, pp. 515-526. https://doi.org/10.1111/1742-6723.12159
Kline, Jeffrey A. ; Hernandez, Jackeline ; Hogg, Melanie M. ; Jones, Alan E. ; Courtney, D. Mark ; Kabrhel, Christopher ; Nordenholz, Kristen E. ; Diercks, Deborah B. ; Rondina, Matthew T. ; Klinger, James R. / Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. In: EMA - Emergency Medicine Australasia. 2013 ; Vol. 25, No. 6. pp. 515-526.
@article{0879d1d69adf4eee91adcc8563734731,
title = "Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes",
abstract = "Background: Submassive pulmonary embolism (PE) has a low mortality rate but can degrade functional capacity. Objective: The present study aims to provide rationale, methodology, and initial findings of a multicentre, randomised trial of fibrinolysis for PE that used a composite end-point, including quality of life measures. Methods: This investigator-initiated study was funded by a contract between a corporate partner and the investigator's hospital (the prime site). The investigator was the Food and Drug Administration (FDA) sponsor. The prime site subcontracted, indemnified, and trained consortia members. Consenting, normotensive patients with PE and right ventricular strain (by echocardiography or biomarkers) received low-molecular-weight heparin and random assignment to a single bolus of tenecteplase or placebo in double-blinded fashion. The outcomes were: (i) in-hospital rate of intubation, vasopressor support, and major haemorrhage, or (ii) at 90 days, death, recurrent PE, or composite that defined poor quality of life (echocardiography, 6min walk test and surveys). The planned sample size was n = 200. Results: Eight sites enrolled 87 patients over 5 years. The ratio of patients screened for each enrolled was 7.4 to 1, equating to 11h screening time per patient enrolled. Primary barrier to enrolment was the cost of screening. Two patients died (2.5{\%}, 95{\%}CI [0-8{\%}]), one developed shock, but 18 (22{\%}, 95{\%}CI: [13-30{\%}]) had a poor quality of life. Conclusions: An investigator-initiated, FDA-regulated, multicentre trial of fibrinolysis for submassive PE was conducted, but was limited by screening costs and a low mortality rate. Quality of life measurements might represent a more important patient-centred end-point.",
keywords = "Controlled trial, Fibrinolysis, Indemnification, Methodology, Thrombolysis, Venous thromboembolism",
author = "Kline, {Jeffrey A.} and Jackeline Hernandez and Hogg, {Melanie M.} and Jones, {Alan E.} and Courtney, {D. Mark} and Christopher Kabrhel and Nordenholz, {Kristen E.} and Diercks, {Deborah B.} and Rondina, {Matthew T.} and Klinger, {James R.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1111/1742-6723.12159",
language = "English (US)",
volume = "25",
pages = "515--526",
journal = "EMA - Emergency Medicine Australasia",
issn = "1742-6731",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes

AU - Kline, Jeffrey A.

AU - Hernandez, Jackeline

AU - Hogg, Melanie M.

AU - Jones, Alan E.

AU - Courtney, D. Mark

AU - Kabrhel, Christopher

AU - Nordenholz, Kristen E.

AU - Diercks, Deborah B.

AU - Rondina, Matthew T.

AU - Klinger, James R.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Background: Submassive pulmonary embolism (PE) has a low mortality rate but can degrade functional capacity. Objective: The present study aims to provide rationale, methodology, and initial findings of a multicentre, randomised trial of fibrinolysis for PE that used a composite end-point, including quality of life measures. Methods: This investigator-initiated study was funded by a contract between a corporate partner and the investigator's hospital (the prime site). The investigator was the Food and Drug Administration (FDA) sponsor. The prime site subcontracted, indemnified, and trained consortia members. Consenting, normotensive patients with PE and right ventricular strain (by echocardiography or biomarkers) received low-molecular-weight heparin and random assignment to a single bolus of tenecteplase or placebo in double-blinded fashion. The outcomes were: (i) in-hospital rate of intubation, vasopressor support, and major haemorrhage, or (ii) at 90 days, death, recurrent PE, or composite that defined poor quality of life (echocardiography, 6min walk test and surveys). The planned sample size was n = 200. Results: Eight sites enrolled 87 patients over 5 years. The ratio of patients screened for each enrolled was 7.4 to 1, equating to 11h screening time per patient enrolled. Primary barrier to enrolment was the cost of screening. Two patients died (2.5%, 95%CI [0-8%]), one developed shock, but 18 (22%, 95%CI: [13-30%]) had a poor quality of life. Conclusions: An investigator-initiated, FDA-regulated, multicentre trial of fibrinolysis for submassive PE was conducted, but was limited by screening costs and a low mortality rate. Quality of life measurements might represent a more important patient-centred end-point.

AB - Background: Submassive pulmonary embolism (PE) has a low mortality rate but can degrade functional capacity. Objective: The present study aims to provide rationale, methodology, and initial findings of a multicentre, randomised trial of fibrinolysis for PE that used a composite end-point, including quality of life measures. Methods: This investigator-initiated study was funded by a contract between a corporate partner and the investigator's hospital (the prime site). The investigator was the Food and Drug Administration (FDA) sponsor. The prime site subcontracted, indemnified, and trained consortia members. Consenting, normotensive patients with PE and right ventricular strain (by echocardiography or biomarkers) received low-molecular-weight heparin and random assignment to a single bolus of tenecteplase or placebo in double-blinded fashion. The outcomes were: (i) in-hospital rate of intubation, vasopressor support, and major haemorrhage, or (ii) at 90 days, death, recurrent PE, or composite that defined poor quality of life (echocardiography, 6min walk test and surveys). The planned sample size was n = 200. Results: Eight sites enrolled 87 patients over 5 years. The ratio of patients screened for each enrolled was 7.4 to 1, equating to 11h screening time per patient enrolled. Primary barrier to enrolment was the cost of screening. Two patients died (2.5%, 95%CI [0-8%]), one developed shock, but 18 (22%, 95%CI: [13-30%]) had a poor quality of life. Conclusions: An investigator-initiated, FDA-regulated, multicentre trial of fibrinolysis for submassive PE was conducted, but was limited by screening costs and a low mortality rate. Quality of life measurements might represent a more important patient-centred end-point.

KW - Controlled trial

KW - Fibrinolysis

KW - Indemnification

KW - Methodology

KW - Thrombolysis

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84889684737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889684737&partnerID=8YFLogxK

U2 - 10.1111/1742-6723.12159

DO - 10.1111/1742-6723.12159

M3 - Article

C2 - 24224521

AN - SCOPUS:84889684737

VL - 25

SP - 515

EP - 526

JO - EMA - Emergency Medicine Australasia

JF - EMA - Emergency Medicine Australasia

SN - 1742-6731

IS - 6

ER -